BiomX reports Q3 net loss $7.9M, cash $23.4M, BX004 Part 2 data expected this month

BiomX Inc.

2023-Q3 EPS reported $0.43

Net loss for Q3 2023 was $7.9 million, compared to $6.8 million for Q3 2022.
Cash and equivalents stood at $23.4M as of Sep 30, 2023, down from $34.3M at Dec 31, 2022.
Part 2 data from Phase 1b/2a trial of BX004 for cystic fibrosis expected later in November 2023.
In August 2023, BX004 received FDA Fast Track designation for chronic respiratory infections in CF patients.
Board appointed Edward L. Williams, former executive at Ascendis, Novo Nordisk, and Novartis, in October 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BiomX Inc. reported financial results for for the third quarter ended September 30, 2023.

Period: for the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 14, 2023, BiomX Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

BiomX Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-086410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.